Lesson 24 • 20 Jul 2025
What are the benefits and challenges of using pembrolizumab as an FDA-approved treatment?
Course overview
This course covers muscle-invasive bladder cancer, including diagnostic strategies, treatment advancements, BCG refractory cases, adjuvant therapies, and lymph node dissection, with insights from leading experts in oncology and urology.
2.5 hours, 43 lessons
Lessons
Muscle Invasive Bladder Cancer with Dr. Sia Daneshmand
Lesson 1
How do you determine diagnostic and treatment strategies for bladder tumors?
Lesson 2
How are advancements in MRI and office biopsies influencing bladder cancer treatment and staging?
Lesson 3
What are the key considerations for tumor resection in frail patients, including tissue sampling?
Lesson 4
How are bladder perforations managed differently in muscle invasive versus NMIBC?
Lesson 5
What are preferred treatment approaches for NMIBC including chemotherapy and immunotherapy?
Lesson 6
What are the approaches and challenges in managing various histological subtypes of tumors?
Lesson 7
What are the challenges in treating plasmacytoid variants with chemotherapy and radiation?
Lesson 8
Lesson 9
Describe techniques for performing cystectomy procedures
Lesson 10
Challenges and considerations in treating progressive muscle invasive bladder cancer
Lesson 11
Centralized care and organ-sparing surgeries in bladder cancer
Lesson 12
What are the key considerations for different urinary diversion methods, including neobladders?
Lesson 13
What are the best practices in stoma creation to prevent parastomal hernias?
Multidisciplinary management of BCG refractory NMIBC with Dr. Tim Clinton & Dr. Eugene Pietzak
Lesson 14
How should high-grade non-invasive bladder cancer be managed after initial BCG therapy?
Lesson 15
How is BCG intolerance identified and managed in non-muscle invasive bladder cancer?
Lesson 16
How do you estimate BCG success rates for various high-grade bladder cancer stages and conditions?
Lesson 17
How do BCG shortages impact bladder cancer treatment regimens?
Lesson 18
How do we handle varying patient responses to BCG and explore alternative treatments and trials?
Lesson 19
How are patients with carcinoma in situ (CIS) managed after induction BCG treatment?
Lesson 20
Managing T1 High-Grade Bladder Cancer Recurrence Post-BCG Induction
Lesson 21
What factors influence deciding cystectomy or bladder preservation in T1 high-grade bladder cancer?
Lesson 22
Lesson 23
How is bladder cancer managed after BCG therapy, including the use of blue light cystoscopy?
Lesson 24
What are the benefits and challenges of using pembrolizumab as an FDA-approved treatment?
Adjuvant Therapy for High Risk Bladder Cancer with Dr. Yair Lotan & Dr. Suzanne Cole
Lesson 25
What are the considerations for using neoadjuvant chemotherapy in muscle invasive bladder cancer?
Lesson 26
What are the benefits of administering MVAC chemotherapy for bladder cancer patients?
Lesson 27
How do you decide between surgery and perioperative therapies for bladder cancer?
Lesson 28
When should oncologists discuss chemotherapy with patients post surgery?
Lesson 29
How do different bladder cancer variants respond to chemotherapy?
Lesson 30
How are high-risk patients counseled on chemotherapy and immunotherapy options?
Lesson 31
Lesson 32
What is the current approach to neoadjuvant chemotherapy cycles?
Lesson 33
What are the main considerations for recommending adjuvant radiation therapy in bladder cancer?
Lesson 34
How do findings from the POUT trial influence your approach?
Lymph Node Dissection in the Setting of Bladder Cancer with Seth Lerner
Lesson 35
What is the importance of accurate staging and imaging in bladder cancer?
Lesson 36
How do you talk to patients about the risks of micrometastatic lymph node disease?
Lesson 37
How do you approach lymph node dissection in cancer treatment?
Lesson 38
How Does Radiation Oncology Fit into Trimodal Therapy and Bladder Preservation?
Lesson 39
How Do Patterns in Lymph Node Metastases Impact Surgical Approaches in Bladder Cancer?
Lesson 40
Can you tell us about your clinical trial on node dissection in bladder cancer surgery?
Lesson 41
What are the strict quality control measures and credentialing processes for this trial?
Lesson 42
What are the criteria for extended lymph node dissection in cystectomy patients?
Lesson 43
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.